Delivery Order SPE2DB22D1202-SPE2DB25FVFG1
- Not listed
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 12, 2025, for the supply of HUMIRA (CF) Pen 40 mg/0.4 mL, a pharmaceutical product used to treat autoimmune conditions. This competitively awarded, firm fixed-price delivery order has a ceiling value of $2,265.90 and is set to complete by August 13, 2025. The contract will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. As a non-set-aside award, this...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $3,021.20 on August 13, 2025, for the supply of HUMIRA (CF) Pen 40 mg/0.4 mL. This is a firm fixed-price, non-set-aside competitive award with a performance location in Conshohocken, Pennsylvania, and an ultimate completion date of August 14, 2025. The delivery order represents a single transaction under AmerisourceBergen's larger federal contract vehicle with the Defense Logistics Agency. This delivery...
- The Defense Logistics Agency awarded a $2,416.05 firm fixed price delivery order to AmerisourceBergen Drug Corp on July 28, 2025, for the supply of HUMIRA (CF) Pen 40 mg/0.4 mls, with completion scheduled for July 29, 2025. This non-competitive delivery order was placed against AmerisourceBergen's broader pharmaceutical supply contract vehicle and will be performed at the contractor's facility in Conshohocken, Pennsylvania. HUMIRA is a widely-used biologic medication for treating autoimmune...
- The Defense Logistics Agency awarded a delivery order contract to AmerisourceBergen Drug Corp on July 21, 2025, for the supply of HUMIRA (CF) Pen 40 mg/0.4 mL medication. This is a firm fixed-price delivery order valued at $33,364.14, with an ultimate completion date of July 22, 2025. The award carries no set-aside designation, indicating it was competitively awarded. The place of performance is listed as Conshohocken, Pennsylvania, where AmerisourceBergen maintains its corporate headquarters....
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 13, 2025, for the supply of HUMIRA (CF) Pen 40 mg/0.4 mls, a specialty pharmaceutical product used in the treatment of autoimmune conditions. This firm fixed-price delivery order, valued at $11,500.66, is scheduled for completion by August 14, 2025, with performance to be executed at AmerisourceBergen's facility in Conshohocken, Pennsylvania. The contract was competitively awarded with no set-aside...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 25, 2025, for the supply of HUMIRA (CF) Pen 40 mg/0.4 mL pharmaceutical products, with a ceiling value of $20,552.85. This firm fixed price, non-set-aside delivery order is scheduled for completion by July 28, 2025, and will be performed at the vendor's corporate office location in Conshohocken, Pennsylvania. The award represents a routine pharmaceutical supply transaction under the federal medical...
- The Defense Logistics Agency awarded a $13,333.53 delivery order to AmerisourceBergen Drug Corp for HUMIRA (CF) Pen 40 mg/0.4 mL on July 25, 2025, with an ultimate completion date of July 28, 2025. This firm fixed price contract represents a non-competitive set-aside award and will be performed at the contractor's facility in Conshohocken, Pennsylvania. HUMIRA is a widely-used biologic medication for treating autoimmune conditions, and this delivery order fulfills immediate pharmaceutical supply...
- The Defense Logistics Agency awarded a $9,183.92 delivery order to AmerisourceBergen Drug Corp for HUMIRA (CF) Pen 40 mg/0.4 mls on July 29, 2025, with a completion date of July 30, 2025. This competitively awarded, firm fixed-price contract carries no set-aside designation and represents a single delivery under AmerisourceBergen's broader pharmaceutical supply agreement with DLA. The product will be delivered to AmerisourceBergen's distribution facility in Conshohocken, Pennsylvania. This...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a $2,265.90 delivery order on July 18, 2025, for HUMIRA (CF) Pen 40 mg/0.4 mls, with completion scheduled for July 21, 2025. This competitive award, issued under firm fixed pricing with no set-aside designation, represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) vehicle with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 through December 2026. The pharmaceutical product...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for HUMIRA (CF) Pen 40 mg/0.4 mL pharmaceutical product on July 28, 2025, with a ceiling value of $2,004.19 and a firm fixed price structure. This is a non-set-aside competitive award with an ultimate completion date of July 29, 2025, to be fulfilled at AmerisourceBergen's Conshohocken, Pennsylvania location. The delivery order represents a child contract action under AmerisourceBergen's broader pharmaceutical...
- SPE2DB22D1202Indefinite Delivery Contract
- SPE2DB22D1202-SPE2DB25FVFG1Delivery Order
The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 22, 2025, for the supply of HUMIRA (CF) Pen 40 mg/0.4 mL, with a ceiling value of $38,928.73. This competitively awarded, firm fixed-price delivery order is scheduled for completion by July 23, 2025, with performance to be executed at AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. The contract carries no set-aside designation, reflecting open competition in the federal procurement process. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX and valued at $999,999,999.00 through December 2026. The parent IDC serves as a comprehensive global pharmaceutical support vehicle enabling AmerisourceBergen to supply a broad range of pharmaceutical products and medical supplies to support military healthcare programs worldwide. HUMIRA, a leading immunosuppressant biologic therapy, represents the type of specialty pharmaceutical product procured through this vehicle to support Defense Health Agency operations and other federal healthcare systems.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $38.9k | 7/22/25 |